Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.41 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342785 | 1.00 | NR1H2 (0.43) | NR1H2HSD11B1HSD11B2ITGB3ITGA2B | |
| SCHEMBL342787 | 1.00 | NR1H2 (0.43) | NR1H2HSD11B1HSD11B2ITGB3ITGA2B | |
| SCHEMBL28699400 | 0.84 | NR1H2 (0.56) | NR1H2 | |
| SCHEMBL2201456 | 0.84 | NR1H2 (0.56) | NR1H2 | |
| SCHEMBL28485556 | 0.84 | NR1H2 (0.56) | NR1H2 | |
| SCHEMBL23933627 | 0.84 | NR1H2 (0.56) | NR1H2 | |
| SCHEMBL474868 | 0.81 | HSD11B1 (0.37) | NR1H2HSD11B1 | |
| SCHEMBL342926 | 0.78 | NR1H2 (0.76) | NR1H2 | |
| SCHEMBL10093469 | 0.78 | NR1H2 (0.76) | NR1H2 | |
| SCHEMBL342925 | 0.78 | NR1H2 (0.76) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367690-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | VERTEX PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | disclosed |
| CN-102497863-A | Novel aminopyridine derivatives having Aurora a selective inhibitory action | MSD KK | 2012-06-13 | — | — | CN | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | NR1H2 3181/4885HSD11B1 1948/4885HSD11B2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.